4:31 PM ET
10-Q
Financial Results
Oncotelic Therapeutics Q3 2026 Results: Net Loss of $1.11M, Loss Widens
Oncotelic Therapeutics reported a net loss of $2.92 million for the nine months ended September 30, 2026, compared to a loss of $1.07 million in the prior year period. The company's balance sheet is dominated by a $388 million investment in GMP Bio at fair value, while it continues to manage significant debt obligations and a working capital deficit.
- Key figure
- Net loss $1.11M